Latest filingAug 24, 2026Most recent Form 4
TBPH
Theravance Biopharma, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$00 sells
Net open-market+$05 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period5transactions
- F · Tax withholding · dominant5 · 100%
Activity by reported role
A joint filing can contribute to multiple roles12transactions
- SVP · dominant4 · 33%
- Chief executive officer1 · 8%
- Chief financial officer1 · 8%
- COMM1 · 8%
- DEV1 · 8%
- GC1 · 8%
- HIO1 · 8%
- MA1 · 8%
- SECY1 · 8%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (5)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeFarnum RhondaOrdinary Shares · Direct
226,790Aug 20, 2026
Grimaud Brett A.Ordinary Shares · Direct
355,168Aug 20, 2026
Miller AineOrdinary Shares · Direct
189,826Aug 20, 2026
Sawaf AzizOrdinary Shares · Direct
336,841Aug 20, 2026
Winningham Rick EOrdinary Shares · Direct
1,611,022Aug 20, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Top insiders
By absolute net value across the selected period- WE-$339.6k
- SA-$137.5k
- GA-$134.8k
- MA-$106.1k
- FR-$96.1k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
TBPH transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| TBPH | Winningham Rick E | CEO | withholding | 20.0k | -$33.9M | F | −0.1% | 08/24 | 08/20 | |
| TBPH | Sawaf Aziz | SVPCFO | withholding | 8.11k | -$13.7M | F | −0.1% | 08/24 | 08/20 | |
| TBPH | Miller Aine | SVPDEVHIO | withholding | 6.25k | -$10.6M | F | −0.1% | 08/24 | 08/20 | |
| TBPH | Grimaud Brett A. | SVPGCSECY | withholding | 7.95k | -$13.4M | F | −0.1% | 08/24 | 08/20 | |
| TBPH | Farnum Rhonda | SVPCOMMMA | withholding | 5.66k | -$9.60M | F | −0.1% | 08/24 | 08/20 |
Theravance Biopharma, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Theravance Biopharma, Inc.?
Winningham Rick E, Sawaf Aziz, Miller Aine, Grimaud Brett A., Farnum Rhonda.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
No code-P purchases or code-S sales were reported in the selected period.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.